secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2022-06-27T23:59:59+00:00
Accession:  0001193125-22-182838
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology closes $275M sale of Cullinan Pearl to Taiho; co-development deal for CLN-081
--------------------------------------------------------------------------------

- Upfront cash payment of $275M from Taiho; potential $130M in regulatory milestones for CLN-081/TAS6417.
- Taiho obtains exclusive global rights outside U.S.; companies co-develop and co-commercialize CLN-081 in U.S.
- U.S. profits and development costs split 50/50 between Cullinan and Taiho; Cullinan retains co-commercialization option.
- Deal includes sale of Cullinan Pearl Corp., which holds ex-Japan rights to CLN-081/TAS6417.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522182838/0001193125-22-182838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522182838/d278047d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-182838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer